What the research found
Researchers analysed genetic data from over 140,000 people across three large biobanks, UK Biobank, All of Us (USA), and the Danish National Biobank. They compared GLP-1 drug response (measured by weight loss and HbA1c reduction) against whole-genome sequencing data in participants who had been prescribed semaglutide or liraglutide.
The finding was striking: a cluster of rare and common variants in the GLP1R gene, which encodes the GLP-1 receptor protein, was strongly associated with significantly blunted drug response. Carriers of these variants lost an average of just 2.3% body weight on semaglutide versus 12.8% in non-carriers on the same dose and duration. Their HbA1c improvements were similarly attenuated.
"This explains something clinicians have observed for years but couldn't account for, a subset of patients who do everything right but simply don't respond the way we'd expect. It's not behavioural. It's biological.", Senior author, June 2026
How GLP-1 resistance works biologically
GLP-1 receptor agonists work by binding to the GLP-1 receptor (GLP1R) on pancreatic beta cells, gut cells, and brain neurons. This binding triggers several cascades: increased insulin secretion, reduced glucagon release, delayed gastric emptying, and, critically for weight loss, satiety signalling to the hypothalamus.
The newly identified variants alter the three-dimensional structure of the GLP1R protein in ways that reduce binding affinity or impair downstream signalling. The drug still attaches to the receptor, but the cellular response is significantly blunted. Think of it like a key that fits the lock but doesn't fully turn, the door only partially opens.
GLP-1 responders vs non-responders: what the difference looks like
Could this explain your experience with Ozempic?
If you or a patient have been on a GLP-1 drug at therapeutic dose for 12-16 weeks with minimal weight loss or glycaemic benefit, GLP-1 resistance is now a clinically plausible explanation, though not the only one. Before attributing non-response to genetics, clinicians should first exclude:
- Subtherapeutic dosing: Many patients are maintained at lower doses due to side effects without reaching the therapeutic dose (2.4mg semaglutide weekly for obesity)
- Injection technique: Subcutaneous injection into fat rather than muscle is essential, common errors reduce bioavailability
- Dietary compensation: GLP-1 drugs reduce appetite but don't override caloric excess if eating behaviour hasn't changed
- Drug interactions: Some medications reduce GLP-1 efficacy
- Adherence: Missed doses significantly blunt the sustained effect
If all of the above are optimised and response remains minimal after 16 weeks, GLP-1 resistance genetic testing is now a reasonable next conversation with your clinician.
Alternatives if GLP-1 drugs aren't working
| Alternative | Mechanism | Evidence for GLP-1 non-responders |
|---|---|---|
| Tirzepatide (Mounjaro) | Dual GIP + GLP-1 receptor agonist | GIP receptor pathway unaffected by GLP1R variants, promising early data |
| Bariatric surgery | Mechanical + hormonal | Most effective long-term weight loss, not receptor dependent |
| Naltrexone/bupropion (Contrave) | Central appetite suppression | Different mechanism, may work in GLP-1 non-responders |
| Orlistat | Pancreatic lipase inhibitor | Peripheral mechanism, not affected by GLP1R variants |
| Intensive lifestyle + dietitian | Behavioural + metabolic | Effective regardless of genotype |
What this means for prescribing practice
This discovery has immediate practical implications. Firstly, clinicians should not automatically escalate GLP-1 doses or extend treatment duration in non-responders without considering pharmacogenomic resistance as a differential. Continuing expensive, supply-constrained medication in confirmed non-responders is poor resource stewardship and exposes patients to unnecessary side effects without benefit.
Secondly, this opens the door to precision prescribing in obesity medicine. Within 2-3 years, pharmacogenomic testing for GLP1R variants may become standard pre-prescribing practice, similar to how BRCA testing shapes breast cancer treatment decisions today.
Use our BMI Calculator to track progress objectively, and our Framingham Risk Score to monitor cardiovascular risk improvement, or lack thereof, during treatment.
Frequently Asked Questions
References
- Nissen SE, et al. "Pharmacogenomics of GLP-1 receptor agonist response: identification of GLP1R loss-of-function variants." Nature Medicine. 2026.
- Davies M, et al. "Semaglutide 2·4 mg once a week in adults with overweight or obesity (STEP 1): a randomised, double-blind, placebo-controlled, phase 3 trial." Lancet. 2021;397(10278):971-984.
- Drucker DJ. "GLP-1 physiology informs the pharmacotherapy of obesity." Molecular Metabolism. 2022;57:101351.